Noble Financial Comments on Zomedica FY2024 Earnings

Zomedica Corp. (NYSEAMERICAN:ZOM) – Analysts at Noble Financial issued their FY2024 earnings estimates for shares of Zomedica in a research report issued on Monday, November 11th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings per share of ($0.05) for the year. Noble Financial has a “Strong-Buy” rating on the stock. Noble Financial also issued estimates for Zomedica’s Q4 2024 earnings at ($0.01) EPS, Q1 2025 earnings at ($0.01) EPS, Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at ($0.01) EPS, FY2025 earnings at ($0.03) EPS, FY2026 earnings at ($0.03) EPS and FY2027 earnings at ($0.03) EPS.

Zomedica Price Performance

Shares of ZOM stock opened at $0.15 on Thursday. Zomedica has a fifty-two week low of $0.12 and a fifty-two week high of $0.23.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Zomedica stock. Virtu Financial LLC boosted its holdings in shares of Zomedica Corp. (NYSEAMERICAN:ZOM) by 1,585.0% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 168,773 shares of the company’s stock after acquiring an additional 158,757 shares during the quarter. Virtu Financial LLC’s holdings in Zomedica were worth $25,000 at the end of the most recent quarter. Institutional investors and hedge funds own 8.95% of the company’s stock.

Zomedica Company Profile

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system.